CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the US Food and Drug Administration (“FDA”) for the treatment of chronic allograft nephropathy. Chronic allograft nephropathy (CAN), also known as chronic allograft dysfunction, is a fibrotic condition that is a leading cause of kidney transplant failure. Approximately 20% of patients on the waiting list for kidney transplantation in the United States are awaiting a retransplant of a failed graft. There are no FDA-approved therapies for CAN.
